

New skin Cancer Drug

Pembrolizumab, a humanised monoclonal antibody, formerly known as lambrolizumab, also referred to by the name MK-3475, is a monoclonal antibody immunotherapy being developed for the treatment of cancer. The antibody targets PD-1 receptor, a cell surface protein molecule. This can enhance the T-cell response and encourage the body's own immune system to kill the cancer cells

- Pembrolizumab tackles [melanoma](#), the deadliest form of skin cancer – and a cancer that often spreads to other parts of the body. 2.3% of skin cancers are melanoma, however melanoma is responsible for 75% of skin cancer deaths.
- this antibody itself is interesting as it works by activating the body's own immune response in order to kill the cancer

Reference

<http://www.totalbiopharma.com/2014/06/23/immunotherapy-antibodies-treatment-melanoma-next-blockbuster/>